Vaccinia virus (VACV) is an enveloped DNA virus from the Orthopoxvirus family, various strains of which were used in the successful eradication campaign against smallpox. Both original and newer VACV-based replicating vaccines reveal a risk of serious complications in atopic individuals. VACV encodes various factors interfering with host immune responses at multiple levels. In atopic skin, the production of type I interferon is compromised, while VACV specifically inhibits the phosphorylation of the Interferon Regulatory Factor 3 (IRF-3) and expression of interferons. To overcome this block, we generated a recombinant VACV-expressing murine IRF-3 (WR-IRF3) and characterized its effects on virus growth, cytokine expression and apoptosis in tissue cultures and in spontaneously atopic Nc/Nga and control Balb/c mice. Further, we explored the induction of protective immune responses against a lethal dose of wild-type WR, the surrogate of smallpox. We demonstrate that the overexpression of IRF-3 by WR-IRF3 increases the expression of type I interferon, modulates the expression of several cytokines and induces superior protective immune responses against a lethal poxvirus challenge in both Nc/Nga and Balb/c mice. Additionally, the results may be informative for design of other virus-based vaccines or for therapy of different viral infections.

BIOCEV Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University in Vestec Průmyslová 595 252 50 Vestec Czech Republic

Department of Immunology and Microbiology 1st Faculty of Medicine Charles University Studnickova 7 128 00 Prague 2 Czech Republic

See more in PubMed

Artenstein A.W. New generation smallpox vaccines: A review of preclinical and clinical data. Rev. Med. Virol. 2008;18:217–231. doi: 10.1002/rmv.571. PubMed DOI

Jacobs B.L., Langland J.O., Kibler K.V., Denzler K.L., White S.D., Holechek S.A., Wong S., Huynh T., Baskin C.R. Vaccinia virus vaccines: Past, present and future. Antiviral Res. 2009;84:1–13. doi: 10.1016/j.antiviral.2009.06.006. PubMed DOI PMC

Engler R.J., Kenner J., Leung D.Y. Smallpox vaccination: Risk considerations for patients with atopic dermatitis. J. Allergy Clin. Immunol. 2002;110:357–365. doi: 10.1067/mai.2002.128052. PubMed DOI

Knitlova J., Hajkova V., Voska L., Elsterova J., Obrova B., Melkova Z. Development of eczema vaccinatum in atopic mouse models and efficacy of MVA vaccination against lethal poxviral infection. PLoS ONE. 2014;9:e114374. doi: 10.1371/journal.pone.0114374. PubMed DOI PMC

Werfel T., Allam J.P., Biedermann T., Eyerich K., Gilles S., Guttman-Yassky E., Hoetzenecker W., Knol E., Simon H.U., Wollenberg A., et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J. Allergy Clin. Immunol. 2016;138:336–349. doi: 10.1016/j.jaci.2016.06.010. PubMed DOI

Mansouri Y., Guttman-Yassky E. Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics. J. Clin. Med. 2015;4:858–873. doi: 10.3390/jcm4050858. PubMed DOI PMC

Wollenberg A., Wagner M., Gunther S., Towarowski A., Tuma E., Moderer M., Rothenfusser S., Wetzel S., Endres S., Hartmann G. Plasmacytoid dendritic cells: A new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J. Investig. Dermatol. 2002;119:1096–1102. doi: 10.1046/j.1523-1747.2002.19515.x. PubMed DOI

Kawakami Y., Tomimori Y., Yumoto K., Hasegawa S., Ando T., Tagaya Y., Crotty S., Kawakami T. Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum. J. Exp. Med. 2009;206:1219–1225. doi: 10.1084/jem.20082835. PubMed DOI PMC

Howell M.D., Wollenberg A., Gallo R.L., Flaig M., Streib J.E., Wong C., Pavicic T., Boguniewicz M., Leung D.Y. Cathelicidin deficiency predisposes to eczema herpeticum. J. Allergy Clin. Immunol. 2006;117:836–841. doi: 10.1016/j.jaci.2005.12.1345. PubMed DOI PMC

Howell M.D., Gallo R.L., Boguniewicz M., Jones J.F., Wong C., Streib J.E., Leung D.Y. Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity. 2006;24:341–348. doi: 10.1016/j.immuni.2006.02.006. PubMed DOI

Ou L.S., Goleva E., Hall C., Leung D.Y. T regulatory cells in atopic dermatitis and subversion of their activity by superantigens. J. Allergy Clin. Immunol. 2004;113:756–763. doi: 10.1016/j.jaci.2004.01.772. PubMed DOI

Kohara Y., Tanabe K., Matsuoka K., Kanda N., Matsuda H., Karasuyama H., Yonekawa H. A major determinant quantitative-trait locus responsible for atopic dermatitis-like skin lesions in NC/Nga mice is located on Chromosome 9. Immunogenetics. 2001;53:15–21. doi: 10.1007/s002510000286. PubMed DOI

Suto H., Matsuda H., Mitsuishi K., Hira K., Uchida T., Unno T., Ogawa H., Ra C. NC/Nga mice: A mouse model for atopic dermatitis. Int. Arch. Allergy Immunol. 1999;120((Suppl. 1)):70–75. doi: 10.1159/000053599. PubMed DOI

Smith G.L., Benfield C.T.O., Maluquer de Motes C., Mazzon M., Ember S.W.J., Ferguson B.J., Sumner R.P. Vaccinia virus immune evasion: Mechanisms, virulence and immunogenicity. J. Gen. Virol. 2013;94:2367–2392. doi: 10.1099/vir.0.055921-0. PubMed DOI

Smith G.L., Talbot-Cooper C., Lu Y. How Does Vaccinia Virus Interfere With Interferon? Adv. Virus Res. 2018;100:355–378. doi: 10.1016/bs.aivir.2018.01.003. PubMed DOI

Unterholzner L., Sumner R.P., Baran M., Ren H., Mansur D.S., Bourke N.M., Randow F., Smith G.L., Bowie A.G. Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor proteins and inhibits activation of IRF3 and IRF7. PLoS Pathog. 2011;7:e1002247. doi: 10.1371/journal.ppat.1002247. PubMed DOI PMC

Ferguson B.J., Benfield C.T.O., Ren H., Lee V.H., Frazer G.L., Strnadova P., Sumner R.P., Smith G.L. Vaccinia virus protein N2 is a nuclear IRF3 inhibitor that promotes virulence. J. Gen. Virol. 2013;94:2070–2081. doi: 10.1099/vir.0.054114-0. PubMed DOI PMC

Liskova J., Knitlova J., Honner R., Melkova Z. Apoptosis and necrosis in vaccinia virus-infected HeLa G and BSC-40 cells. Virus Res. 2011;160:40–50. doi: 10.1016/j.virusres.2011.05.005. PubMed DOI

Benfield C.T.O., Ren H., Lucas S.J., Bahsoun B., Smith G.L. Vaccinia virus protein K7 is a virulence factor that alters the acute immune response to infection. J. Gen. Virol. 2013;94:1647–1657. doi: 10.1099/vir.0.052670-0. PubMed DOI PMC

Mansur D.S., Maluquer de Motes C., Unterholzner L., Sumner R.P., Ferguson B.J., Ren H., Strnadova P., Bowie A.G., Smith G.L. Poxvirus targeting of E3 ligase beta-TrCP by molecular mimicry: A mechanism to inhibit NF-kappaB activation and promote immune evasion and virulence. PLoS Pathog. 2013;9:e1003183. doi: 10.1371/journal.ppat.1003183. PubMed DOI PMC

Kalbacova M., Spisakova M., Liskova J., Melkova Z. Lytic infection with vaccinia virus activates caspases in a Bcl-2-inhibitable manner. Virus Res. 2008;135:53–63. doi: 10.1016/j.virusres.2008.02.007. PubMed DOI

Melkova Z., Esteban M. Interferon-gamma severely inhibits DNA synthesis of vaccinia virus in a macrophage cell line. Virology. 1994;198:731–735. doi: 10.1006/viro.1994.1087. PubMed DOI

Kalbacova M., Vrbacky M., Humlova Z., Melkova Z. Protooncogene Bcl-2 induces apoptosis in several cell lines. Folia Biol. (Praha) 2002;48:15–27. PubMed

Rodriguez J.F., Rodriguez D., Rodriguez J.R., McGowan E.B., Esteban M. Expression of the firefly luciferase gene in vaccinia virus: A highly sensitive gene marker to follow virus dissemination in tissues of infected animals. Proc. Natl. Acad. Sci. USA. 1988;85:1667–1671. doi: 10.1073/pnas.85.5.1667. PubMed DOI PMC

Mackett M., Smith G.L., Moss B. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J. Virol. 1984;49:857–864. doi: 10.1128/jvi.49.3.857-864.1984. PubMed DOI PMC

Spisakova M., Cizek Z., Melkova Z. Ethacrynic and alpha-lipoic acids inhibit vaccinia virus late gene expression. Antiviral Res. 2009;81:156–165. doi: 10.1016/j.antiviral.2008.11.001. PubMed DOI PMC

Joklik W.K. The preparation and characteristics of highly purified radioactively labelled poxvirus. Biochim. Biophys Acta. 1962;61:290–301. doi: 10.1016/0926-6550(62)90091-9. PubMed DOI

Castellaneta A., Yoshida O., Kimura S., Yokota S., Geller D.A., Murase N., Thomson A.W. Plasmacytoid dendritic cell-derived IFN-alpha promotes murine liver ischemia/reperfusion injury by induction of hepatocyte IRF-1. Hepatology. 2014;60:267–277. doi: 10.1002/hep.27037. PubMed DOI PMC

Cogswell J.P., Godlevski M.M., Wisely G.B., Clay W.C., Leesnitzer L.M., Ways J.P., Gray J.G. NF-kappa B regulates IL-1 beta transcription through a consensus NF-kappa B binding site and a nonconsensus CRE-like site. J. Immunol. 1994;153:712–723. PubMed

Chattopadhyay S., Marques J.T., Yamashita M., Peters K.L., Smith K., Desai A., Williams B.R., Sen G.C. Viral apoptosis is induced by IRF-3-mediated activation of Bax. EMBO J. 2010;29:1762–1773. doi: 10.1038/emboj.2010.50. PubMed DOI PMC

Gherardi M.M., Ramirez J.C., Rodriguez D., Rodriguez J.R., Sano G., Zavala F., Esteban M. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner. J. Immunol. 1999;162:6724–6733. PubMed

von Sonnenburg F., Perona P., Darsow U., Ring J., von Krempelhuber A., Vollmar J., Roesch S., Baedeker N., Kollaritsch H., Chaplin P. Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis. Vaccine. 2014;32:5696–5702. doi: 10.1016/j.vaccine.2014.08.022. PubMed DOI

Greenberg R.N., Hurley M.Y., Dinh D.V., Mraz S., Vera J.G., von Bredow D., von Krempelhuber A., Roesch S., Virgin G., Arndtz-Wiedemann N., et al. A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis. PLoS ONE. 2015;10:e0138348. doi: 10.1371/journal.pone.0138348. PubMed DOI PMC

Pittman P.R., Hahn M., Lee H.S., Koca C., Samy N., Schmidt D., Hornung J., Weidenthaler H., Heery C.R., Meyer T.P.H., et al. Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox. N. Engl. J. Med. 2019;381:1897–1908. doi: 10.1056/NEJMoa1817307. PubMed DOI

Yokote H., Shinmura Y., Kanehara T., Maruno S., Kuranaga M., Matsui H., Hashizume S. Safety of attenuated smallpox vaccine LC16m8 in immunodeficient mice. Clin. Vaccine Immunol. 2014;21:1261–1266. doi: 10.1128/CVI.00199-14. PubMed DOI PMC

Danon Y.L., Sutter G. Use of the LC16m8 Smallpox Vaccine in Immunocompromised Individuals Is Still Too Risky. Clin. Vaccine Immunol. 2015;22:604. doi: 10.1128/CVI.00782-14. PubMed DOI PMC

Ahn J., Barber G.N. STING signaling and host defense against microbial infection. Exp. Mol. Med. 2019;51:1–10. doi: 10.1038/s12276-019-0333-0. PubMed DOI PMC

Ni G., Ma Z., Damania B. cGAS and STING: At the intersection of DNA and RNA virus-sensing networks. PLoS Pathog. 2018;14:e1007148. doi: 10.1371/journal.ppat.1007148. PubMed DOI PMC

Glanz A., Chakravarty S., Varghese M., Kottapalli A., Fan S., Chakravarti R., Chattopadhyay S. Transcriptional and Non-Transcriptional Activation, Posttranslational Modifications, and Antiviral Functions of Interferon Regulatory Factor 3 and Viral Antagonism by the SARS-Coronavirus. Viruses. 2021;13:575. doi: 10.3390/v13040575. PubMed DOI PMC

Servant M.J., ten Oever B., LePage C., Conti L., Gessani S., Julkunen I., Lin R., Hiscott J. Identification of distinct signaling pathways leading to the phosphorylation of interferon regulatory factor 3. J. Biol. Chem. 2001;276:355–363. doi: 10.1074/jbc.M007790200. PubMed DOI

Reed J.L., Scott D.E., Bray M. Eczema vaccinatum. Clin. Infect. Dis. 2012;54:832–840. doi: 10.1093/cid/cir952. PubMed DOI

Thanos D., Maniatis T. Virus induction of human IFN beta gene expression requires the assembly of an enhanceosome. Cell. 1995;83:1091–1100. doi: 10.1016/0092-8674(95)90136-1. PubMed DOI

Panne D., Maniatis T., Harrison S.C. An atomic model of the interferon-beta enhanceosome. Cell. 2007;129:1111–1123. doi: 10.1016/j.cell.2007.05.019. PubMed DOI PMC

Garoufalis E., Kwan I., Lin R., Mustafa A., Pepin N., Roulston A., Lacoste J., Hiscott J. Viral induction of the human beta interferon promoter: Modulation of transcription by NF-kappa B/rel proteins and interferon regulatory factors. J. Virol. 1994;68:4707–4715. doi: 10.1128/jvi.68.8.4707-4715.1994. PubMed DOI PMC

Roth S., Rottach A., Lotz-Havla A.S., Laux V., Muschaweckh A., Gersting S.W., Muntau A.C., Hopfner K.P., Jin L., Vanness K., et al. Rad50-CARD9 interactions link cytosolic DNA sensing to IL-1beta production. Nat. Immunol. 2014;15:538–545. doi: 10.1038/ni.2888. PubMed DOI PMC

Aarreberg L.D., Wilkins C., Ramos H.J., Green R., Davis M.A., Chow K., Gale M., Jr. Interleukin-1beta Signaling in Dendritic Cells Induces Antiviral Interferon Responses. mBio. 2018;9 doi: 10.1128/mBio.00342-18. PubMed DOI PMC

Abe T., Barber G.N. Cytosolic-DNA-mediated, STING-dependent proinflammatory gene induction necessitates canonical NF-kappaB activation through TBK1. J. Virol. 2014;88:5328–5341. doi: 10.1128/JVI.00037-14. PubMed DOI PMC

Yum S., Li M., Fang Y., Chen Z.J. TBK1 recruitment to STING activates both IRF3 and NF-kappaB that mediate immune defense against tumors and viral infections. Proc. Natl. Acad. Sci. USA. 2021;118 doi: 10.1073/pnas.2100225118. PubMed DOI PMC

Fang R., Wang C., Jiang Q., Lv M., Gao P., Yu X., Mu P., Zhang R., Bi S., Feng J.M., et al. NEMO-IKKbeta Are Essential for IRF3 and NF-kappaB Activation in the cGAS-STING Pathway. J. Immunol. 2017;199:3222–3233. doi: 10.4049/jimmunol.1700699. PubMed DOI

Guarda G., Braun M., Staehli F., Tardivel A., Mattmann C., Forster I., Farlik M., Decker T., Du Pasquier R.A., Romero P., et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity. 2011;34:213–223. doi: 10.1016/j.immuni.2011.02.006. PubMed DOI

Castiglia V., Piersigilli A., Ebner F., Janos M., Goldmann O., Dambock U., Kroger A., Weiss S., Knapp S., Jamieson A.M., et al. Type I Interferon Signaling Prevents IL-1beta-Driven Lethal Systemic Hyperinflammation during Invasive Bacterial Infection of Soft Tissue. Cell Host Microbe. 2016;19:375–387. doi: 10.1016/j.chom.2016.02.003. PubMed DOI

Tarassishin L., Loudig O., Bauman A., Shafit-Zagardo B., Suh H.S., Lee S.C. Interferon regulatory factor 3 inhibits astrocyte inflammatory gene expression through suppression of the proinflammatory miR-155 and miR-155*. Glia. 2011;59:1911–1922. doi: 10.1002/glia.21233. PubMed DOI PMC

Kettle S., Alcami A., Khanna A., Ehret R., Jassoy C., Smith G.L. Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1beta-converting enzyme and protects virus-infected cells from TNF- and Fas-mediated apoptosis, but does not prevent IL-1beta-induced fever. Pt 3J. Gen. Virol. 1997;78:677–685. doi: 10.1099/0022-1317-78-3-677. PubMed DOI

Lopez-Castejon G., Brough D. Understanding the mechanism of IL-1beta secretion. Cytokine Growth Factor Rev. 2011;22:189–195. doi: 10.1016/j.cytogfr.2011.10.001. PubMed DOI PMC

Hornung V., Ablasser A., Charrel-Dennis M., Bauernfeind F., Horvath G., Caffrey D.R., Latz E., Fitzgerald K.A. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature. 2009;458:514–518. doi: 10.1038/nature07725. PubMed DOI PMC

Gerlic M., Faustin B., Postigo A., Yu E.C., Proell M., Gombosuren N., Krajewska M., Flynn R., Croft M., Way M., et al. Vaccinia virus F1L protein promotes virulence by inhibiting inflammasome activation. Proc. Natl. Acad. Sci. USA. 2013;110:7808–7813. doi: 10.1073/pnas.1215995110. PubMed DOI PMC

Isaacs A., Lindenmann J. Virus interference. I. The interferon. Proc. R Soc. Lond B Biol. Sci. 1957;147:258–267. doi: 10.1098/rspb.1957.0048. PubMed DOI

Lee S.B., Melkova Z., Yan W., Williams B.R., Hovanessian A.G., Esteban M. The interferon-induced double-stranded RNA-activated human p68 protein kinase potently inhibits protein synthesis in cultured cells. Virology. 1993;192:380–385. doi: 10.1006/viro.1993.1048. PubMed DOI

Rivas C., Gil J., Melkova Z., Esteban M., Diaz-Guerra M. Vaccinia virus E3L protein is an inhibitor of the interferon (i.f.n.)-induced 2-5A synthetase enzyme. Virology. 1998;243:406–414. doi: 10.1006/viro.1998.9072. PubMed DOI

Rodriguez J.R., Rodriguez D., Esteban M. Interferon treatment inhibits early events in vaccinia virus gene expression in infected mice. Virology. 1991;185:929–933. doi: 10.1016/0042-6822(91)90575-V. PubMed DOI

Liu G., Zhai Q., Schaffner D.J., Wu A., Yohannes A., Robinson T.M., Maland M., Wells J., Voss T.G., Bailey C., et al. Prevention of lethal respiratory vaccinia infections in mice with interferon-alpha and interferon-gamma. FEMS Immunol. Med. Microbiol. 2004;40:201–206. doi: 10.1016/S0928-8244(03)00358-4. PubMed DOI

Green D.R., Ferguson T., Zitvogel L., Kroemer G. Immunogenic and tolerogenic cell death. Nat. Rev. Immunol. 2009;9:353–363. doi: 10.1038/nri2545. PubMed DOI PMC

Kepp O., Senovilla L., Galluzzi L., Panaretakis T., Tesniere A., Schlemmer F., Madeo F., Zitvogel L., Kroemer G. Viral subversion of immunogenic cell death. Cell Cycle. 2009;8:860–869. doi: 10.4161/cc.8.6.7939. PubMed DOI

Humlova Z., Vokurka M., Esteban M., Melkova Z. Vaccinia virus induces apoptosis of infected macrophages. J. Gen. Virol. 2002;83:2821–2832. doi: 10.1099/0022-1317-83-11-2821. PubMed DOI

Baixeras E., Cebrian A., Albar J.P., Salas J., Martinez A.C., Vinuela E., Revilla Y. Vaccinia virus-induced apoptosis in immature B lymphocytes: Role of cellular Bcl-2. Virus Res. 1998;58:107–113. doi: 10.1016/S0168-1702(98)00105-1. PubMed DOI

Engelmayer J., Larsson M., Subklewe M., Chahroudi A., Cox W.I., Steinman R.M., Bhardwaj N. Vaccinia virus inhibits the maturation of human dendritic cells: A novel mechanism of immune evasion. J. Immunol. 1999;163:6762–6768. PubMed

Heylbroeck C., Balachandran S., Servant M.J., DeLuca C., Barber G.N., Lin R., Hiscott J. The IRF-3 transcription factor mediates Sendai virus-induced apoptosis. J. Virol. 2000;74:3781–3792. doi: 10.1128/JVI.74.8.3781-3792.2000. PubMed DOI PMC

Apelbaum A., Yarden G., Warszawski S., Harari D., Schreiber G. Type I interferons induce apoptosis by balancing cFLIP and caspase-8 independent of death ligands. Mol. Cell Biol. 2013;33:800–814. doi: 10.1128/MCB.01430-12. PubMed DOI PMC

Vestergaard C., Yoneyama H., Murai M., Nakamura K., Tamaki K., Terashima Y., Imai T., Yoshie O., Irimura T., Mizutani H., et al. Overproduction of Th2-specific chemokines in NC/Nga mice exhibiting atopic dermatitis-like lesions. J. Clin. Investig. 1999;104:1097–1105. doi: 10.1172/JCI7613. PubMed DOI PMC

Komastu T., Ireland D.D., Reiss C.S. IL-12 and viral infections. Cytokine Growth Factor Rev. 1998;9:277–285. doi: 10.1016/S1359-6101(98)00017-3. PubMed DOI PMC

Fujikura Y., Kudlackova P., Vokurka M., Krijt J., Melkova Z. The effect of nitric oxide on vaccinia virus-encoded ribonucleotide reductase. Nitric Oxide. 2009;20:114–121. doi: 10.1016/j.niox.2008.09.002. PubMed DOI

Melkova Z., Esteban M. Inhibition of vaccinia virus DNA replication by inducible expression of nitric oxide synthase. J. Immunol. 1995;155:5711–5718. PubMed

Karupiah G., Xie Q.W., Buller R.M., Nathan C., Duarte C., MacMicking J.D. Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science. 1993;261:1445–1448. doi: 10.1126/science.7690156. PubMed DOI

Huang S., Hendriks W., Althage A., Hemmi S., Bluethmann H., Kamijo R., Vilcek J., Zinkernagel R.M., Aguet M. Immune response in mice that lack the interferon-gamma receptor. Science. 1993;259:1742–1745. doi: 10.1126/science.8456301. PubMed DOI

Ma W.T., Yao X.T., Peng Q., Chen D.K. The protective and pathogenic roles of IL-17 in viral infections: Friend or foe? Open Biol. 2019;9:190109. doi: 10.1098/rsob.190109. PubMed DOI PMC

Darling A.R., Freyschmidt E.J., Burton O.T., Koleoglou K.J., Oyoshi M.K., Oettgen H.C. IL-10 suppresses IL-17-mediated dermal inflammation and reduces the systemic burden of Vaccinia virus in a mouse model of eczema vaccinatum. Clin. Immunol. 2014;150:153–160. doi: 10.1016/j.clim.2013.11.010. PubMed DOI PMC

Patera A.C., Pesnicak L., Bertin J., Cohen J.I. Interleukin 17 modulates the immune response to vaccinia virus infection. Virology. 2002;299:56–63. doi: 10.1006/viro.2002.1400. PubMed DOI

Shiohara T., Hayakawa J., Mizukawa Y. Animal models for atopic dermatitis: Are they relevant to human disease? J. Dermatol. Sci. 2004;36:1–9. doi: 10.1016/j.jdermsci.2004.02.013. PubMed DOI

Achdout H., Lustig S., Israely T., Erez N., Politi B., Tamir H., Israeli O., Waner T., Melamed S., Paran N. Induction, treatment and prevention of eczema vaccinatum in atopic dermatitis mouse models. Vaccine. 2017;35:4245–4254. doi: 10.1016/j.vaccine.2017.06.014. PubMed DOI

Leung D.Y., Gao P.S., Grigoryev D.N., Rafaels N.M., Streib J.E., Howell M.D., Taylor P.A., Boguniewicz M., Canniff J., Armstrong B., et al. Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-gamma response. J. Allergy Clin. Immunol. 2011;127:965–973.e5. doi: 10.1016/j.jaci.2011.02.010. PubMed DOI PMC